"Bacteroides fragilis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.
Below are MeSH descriptors whose meaning is more general than "Bacteroides fragilis".
Below are MeSH descriptors whose meaning is more specific than "Bacteroides fragilis".
This graph shows the total number of publications written about "Bacteroides fragilis" by people in this website by year, and whether "Bacteroides fragilis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Bacteroides fragilis" by people in Profiles.
Sofi MH, Wu Y, Ticer T, Schutt S, Bastian D, Choi HJ, Tian L, Mealer C, Liu C, Westwater C, Armeson KE, Alekseyenko AV, Yu XZ. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD. JCI Insight. 2021 02 08; 6(3).
Sofi MH, Johnson BM, Gudi RR, Jolly A, Gaudreau MC, Vasu C. Polysaccharide A-Dependent Opposing Effects of Mucosal and Systemic Exposures to Human Gut Commensal Bacteroides fragilis in Type 1 Diabetes. Diabetes. 2019 10; 68(10):1975-1989.
Santilli AD, Dawson EM, Whitehead KJ, Whitehead DC. Nonmicrobicidal Small Molecule Inhibition of Polysaccharide Metabolism in Human Gut Microbes: A Potential Therapeutic Avenue. ACS Chem Biol. 2018 05 18; 13(5):1165-1172.
Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, Casero RA. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A. 2011 Sep 13; 108(37):15354-9.
White RL, Friedrich LV, Manduru M, Mihm LB, Bosso JA. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis. Diagn Microbiol Infect Dis. 2001 Jan; 39(1):39-47.
Fritz ME, Eke PI, Malmquist J, Hardwick R. Clinical and microbiological observations of early polytetrafluoroethylene membrane exposure in guided bone regeneration. Case reports in primates. J Periodontol. 1996 Mar; 67(3):245-9.
White RL, Kays MB, Friedrich LV, Del Bene VE. Impact of different statistical methodologies on the evaluation of the in-vitro MICs for Bacteroides fragilis of selected cephalosporins and cephamycins. J Antimicrob Chemother. 1993 Jan; 31(1):57-64.
Kays MB, White RL, Friedrich LV, Del Bene VE. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties. Clin Ther. 1991 Sep-Oct; 13(5):596-605.
Del Bene VE, Carek PJ, Twitty JA, Burkey LJ. In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance. Antimicrob Agents Chemother. 1985 May; 27(5):817-20.
Brown JE, Del Bene VE, Collins CD. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrob Agents Chemother. 1981 Feb; 19(2):248-52.